CRISPR-based germline editing should be legally permitted for preventing inheritable genetic diseases.

This debate centered on whether CRISPR-based germline editing should be legally permitted under strict therapeutic frameworks or remain categorically prohibited. The Pro position argued for a regulated pathway to address severe monogenic diseases when preimplantation genetic diagnosis (PGD) fails, emphasizing procreative autonomy and the prevention of suffering. The Con position defended prohibition based on intergenerational risk, the impossibility of informed consent from edited descendants, and the inevitable erosion of the therapy/enhancement boundary.

The Con position ultimately prevailed through superior logical rigor and a devastatingly effective closing argument that synthesized the debate's central tension: the irreconcilable conflict between present-tense therapeutic compassion and future-tense intergenerational justice. While Pro maintained consistent emotional appeal and correctly identified the "homozygous parent" edge case where PGD is biologically impossible, they failed to adequately address the epistemological barrier of proving multi-generational safety—a point Con hammered effectively in Round 4. Pro's reliance on regulatory frameworks as a panacea for safety concerns remained hypothetical and under-specified; they cited the UK HFEA's mitochondrial donation approval as precedent without adequately distinguishing mitochondrial replacement (limited to metabolic function, no nuclear genome modification) from CRISPR nuclear editing (permanent germline alteration with unpredictable pleiotropic effects).

Con's victory was cemented in the final round by refusing to concede the "compassion ground" while demonstrating that Pro's position required gambling with the genetic heritage of non-consenting future persons. However, Con was not without flaws: they hand-waved the homozygous parent scenario toward adoption and gamete donation without engaging with Pro's specific biological constraint, and their slippery-slope arguments occasionally verged on argumentum in terrorem rather than evidence-based prediction. The decisive factor was Con's successful framing of germline editing as categorically distinct from somatic therapy—a distinction Pro acknowledged but failed to overcome—creating an insurmountable burden of proof that Pro's evidence (notably sparse on long-term mammalian germline studies) could not satisfy.